Author Guidelines

Editorial and peer-review evaluation process

The editorial and peer-review evaluation process consists of three steps that can result in approval for the next step, return to the authors or refusal:

(1) Prior to the editorial process, submitted manuscripts are reviewed for manuscript formatting, reference style, limits, registration number (if applicable), research ethics and patient consent (if applicable), and reporting guidelines (if applicable). If any technical aspect is not attended to, the editorial process is interrupted until the authors make the adjustments.

(2) Manuscripts approved in the previous step are evaluated by Scientific Editor for type of article and relevance of the manuscript to pharmaceutical sciences and journal scope. The manuscript may go for Associate Editors, who will evaluate relevance and / or refer peers, peer-review or be rejected, with the authors informed.

(3) Manuscripts approved in the Scientific or Associate Editor step are forwarded for peer-review. adheres to a rigorous double-blind peer-review policy, in which the identity of the reviewers (at least two) and the authors is concealed from both. Considering the recommendations of the reviewers, the Editor decides whether to accept, refuse or need revision by the authors within 20 days. The new version is reviewed by the same reviewers as the original version.

During the submission process, authors are invited to suggest the name and contact information of three reviewers for the manuscript. Recommended reviewers should be experts in the field and not have a conflict of interest (e.g. prior knowledge of your submission, collaboration with at least one author, same institution). Editors are not obliged to invite any recommended reviewers to assess your manuscript.

The Editor or members of the Editorial Board may submit their own manuscripts for possible publication in RCFBA. In these cases, the peer review process will be managed by members of Board. The submitting Editor/ Board member will have no involvement in the decision-making process.

Post preliminary acceptance, final acceptance, and publishing process

After preliminary acceptance by the Scientific Editor and considering peer-review evaluation, manuscripts need to be revised for requirements of peer-reviewed process and language, which is the responsibility of the authors and must be attended to within 20 days, by a professional review certificate. The publication fee does not include language review. Manuscript that do not comply with these requirements, will not receive final acceptance, and will not be published.

Following, the proofs will be made available to the corresponding author through our editing portal or by email, and corrections must be made directly or promptly notified or within 3 days. At this stage, we recommend that authors carefully re-check information regarding the name, ORCID, affiliation, order, contact details, financing statements or conflicts of interest, if applicable.

Please note that if there are any changes to the list of authors at this stage, all authors must complete and sign a form authorizing the change.

Section policies

RCFBA/ JBAPS publishes the following types of contributions:

  • Research Articles: Research articles describe experimental or observational investigations that used formal methods for data collection and presentation of results;
  • Systematic Reviews and Systematic Scoping Reviews of quantitative or qualitative evidence: Systematic reviews in accordance with the methodological guidelines;
  • Narrative Reviews (invited only): Non-systematic review or state-of-the-art summary article. Authors interested should write to the editors prior to submitting;
  • Short Communications: Short Communications are Research Articles but with fewer words, tables, and figures, usually used to publish preliminary results and/or hypotheses;
  • Letters to the Editor (invited only): Letter to a publication, typically commenting upon a published work. Authors interested should write to the editors prior to submitting;
  • Editorials (invited only): Opinion piece, policy statement, or general commentary, typically written by staff of the publication. Authors interested should write to the editors prior to submitting;
  • Corrections, expressions of concern, and retractions will be published whenever required in accordance to the ICMJE recommendations (

Text structure

Research Articles, Systematic Reviews and Systematic Scoping Reviews, and Short Communications must follow the Reporting Guidelines described in the section below, as well as the structure known as IMRaD (Introduction, Methods, Results, and Discussion) - do not aggregate these subheadings - and structured abstract must present Objectives, Methods, including protocol number, Results, and Conclusions. Other manuscript categories (Editorials, Narrative Reviews, Letters to the Editor, and Case Reports) must follow the text and abstract format appropriate to the Reporting Guidelines described in the section below.


The following limits must be observed by the authors before submitting the manuscript.

Contribution type

Abstract word count    

Main text word count   

Table and/or Figures   


Research Articles

       Up to 300

Not limited

Not limited

Not limited

Short Communications

       Up to 300

Up to 2,000

Up to 4

Up to 30

Systematic Reviews

       Up to 300

Not limited

Not limited

Not limited

Narrative Reviews

       Up to 300

Up to 2,000

Not limited

Not limited

Letters to the Editor


Not limited

Not limited

Not limited



Not limited

Not limited

Not limited



Only keywords based on NLM Medical Subject Headings are used.

Open access, license, and copyright

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI (Budapest Open Access Initiative) definition of open access. Accepted articles will be published as Open Access and distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The authors of accepted manuscripts retain shared copyright and agree to have it published by the RCFBA/ JBAPS under the Creative Commons Attribution License ( Under this Open Access license, the author agrees that anyone can reuse their article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited, but not in any way that suggests that the authors endorse them or their use of the work.

Self-archiving policies

Authors are encouraged to self-archive their accepted and published manuscripts by posting them in personal blogs, institutional repositories and scientific social media, as well as on their personal social media, as long as the full citation of the original publication is included.

Language policies

Only manuscripts submitted in English will be accepted for evaluation. The final acceptance will be given only when the authors present a professionally copy-edited English version of the manuscript along with a certificate of revision. The costs of language services must run at the authors expenses and the Editors reserve their right to request further revisions if they see fit.

Authorship and disclosures

Authorship byline

Authors must agree on the manuscript authorship making sure it accurately illustrates and includes contributors who actually and significantly contributed to the work. All those listed as authors should qualify for authorship according to substantial contributions on the concept and design of the work and/or data acquisition and interpretation and evaluation, and should have been actively involved during manuscript revision and approval of the final manuscript version, with substantial and intellectual involvement, specially in the results discussion.

Author contributions and responsibility

All authors must approve the final version of the manuscript and be responsible for each part of collaborative work done in its final version. In addition, each author's specific contribution according to the CRediT's standard designations available at, must be included only in the Cover Letter as outlined in the manuscript preparation guidelines.

Changes in authorship after submission

Any changes in authorship during or after the revision process of the manuscript will only be considered by the editors if important additional experiments or relevant contributions have been made and justified. Such changes in authorship must be requested by email to the journal Editorial Assistant team and need to be described in detail, explaining their rationale for the required changes.


Contributions from anyone who does not meet the authorship criteria should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical support, collaboration of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). This information must be included only in the Cover Letter as outlined in the manuscript preparation guidelines.

Conflict of Interest

Authors are required to include a statement disclosing any potential conflicts of interest. RCFBA/ JBAPS considers potential conflicts of interest any event of a personal, commercial, political, or academic nature, whether or not involving financial compensation. This information must be included only in the Cover Letter as outlined in the manuscript preparation guidelines.

Funding disclosure statement

All financial support received must be disclosed by all authors. Use the author’s initials followed by a short description and include the funding agency’s name and grant identification number(s), in that order. This information must be included only in the Cover Letter as outlined in the manuscript preparation guidelines.

Studies involving humans

RCFBA/ JBAPS adheres to the ICMJE reporting guidelines on protecting research participants, collecting and archiving informed consent when required by the study type, Ethics Committee approval and Clinical trials pre-registration best practices as stated by the Helsinki Declaration as revised in 2013, as well as local legal requirements. Learn more at and

Publishing ethics and malpractice statement

RCFBA/ JBAPS follows the publication best practices recommendations of the Committee on Publication Ethics (COPE) and expects authors, reviewers and editors to act with integrity in all stages of the evaluation and publication process.

Suspicious about potential misconduct cases must be addressed by email directly to the Editor-n-Chief and include a detailed report on the suspected problems.

All misconduct reports will be thoroughly investigated by the editorial board using the COPE Flowcharts and requesting information from the involved parties and/or their institutions. Corrections, expressions of concern and retractions will be published whenever required.

Reporting guidelines

A manuscript must contain sufficient information to promote proper evaluation, reproducibility, and replicability. Therefore, we encourage the use of reporting guidelines:

  • ARRIVE guidelines for animal pre-clinical studies;
  • CHEERS guidelines for economic evaluations;
  • CONSORT guidelines for randomized trials;
  • MOOSE guidelines for meta-analyses and systematic review of observation studies;
  • PRISMA guidelines for systematic reviews and meta-analysis;
  • SRQR or COREQ guidelines for qualitative research;
  • STARD guidelines for diagnostic accuracy studies;
  • STROBE guidelines for observation studies (cohort, case-control, or cross-sectional designs); and
  • STREGA guidelines for genetic association studies.

To find other reporting guidelines see

Data sharing and data statement

We encourage the sharing of data that supports your research (e.g. raw and processed data, video, code, software, algorithms, protocols) by promoting reuse, reducing waste of resources, promoting collaboration, and increasing confidence in the results. Mendeley Data, Dryad, OSF, among others, are secure online repositories that provide a DOI that can be cited in the manuscript references.

We recommend that you indicate the availability of your data in your submission. This may be a requirement of your institution or funder. If your data is not available to access, you can indicate, for example, that the research data is confidential.

Supplementary materials will not be accepted. If your manuscript contains complementary materials, we recommend that you share them in public repositories and reference them properly by the DOI.

Submission files preparation guidelines

During the submission of your manuscript you must upload at least 3 files:

  • title-page.docx:
    This document serves both as a checklist and metadata collection form. It must be prepared using the Title Page template. Authors need to enter the requested information as shown for each field labelled as "Filled by: Author". Read the section Title Page section below for additional information.
  • manuscript.docx:
    This is the main document of your work and it must be carefully prepared according to the journal Policies and Preparation Guidelines.
  • agreement.pdf:
    This document must be read, understood, and signed by all authors.

In addition to the above files, you will also need to upload one or more of the following files, depending on the type of contribution you are submitting:

  • ethics-committee-approval.pdf: this document must be submitted for studies involving Humans (live or tissue), including studies that are observational, survey-based, or include any personal data.

Title Page

This document serves both as a checklist and metadata collection form. It must be prepared using the title-page.docx template. Authors need to enter the requested information as shown for each field labelled as "Filled by: Author".

Important: the template file above has detailed instructions and examples for all fields which must be filled by the author.


This is the main document of your work and it must be carefully prepared according to the journal Policies and Preparation Guidelines.

Important: This document must not have any information that identifies the authors.

Start with the manuscript title, followed by the abstract, keywords and then make sure you follow the specific requirements depending on the type of contribution you are submitting.


Photographs, charts, maps, or illustrations must be submitted at the end of work, numbered consecutively in Arabic numerals in the order that they appear in the text. The corresponding captions should be clear and concise and should appears after each figure.  In the text, the approximate position of each figure must be shown. The figures should be in color, however, in the publication they will appear printed in black and white or grayscale. Photographs should be sent also in separate files outside of Word, in .tif or .jpg format with at least 300 dpi resolution.


These should complement and not duplicate the text. Tables should be numbered in Arabic numerals, in the order in which they appear in the text, and a brief and descriptive title should be placed above each. If necessary, identified footnotes should be used.  Tables must be presented at the end of the text and their position shown in the body of the text.


Reference Style and Format: The Uniform Requirements style for references is based largely on an American National Standards Institute style adapted by the National Library of Medicine (NLM) for its databases. Authors should consult NLM’s Citing Medicine (2007, updated 2009 - for information on its recommended formats for a variety of reference types.

All published work cited in the body of the text must appear in the list of bibliographical references, which should be organized alphabetically, in the style of the Vancouver (author number) system.  Only citations essential to the content of the article should be included.  In publications with up to ten authors, all  of  them  should  be  cited;  beyond  this number, only the first author, followed by the expression “et al.”. Names of journals should be abbreviated in the style used in the Index Medicus (not in italics and without full stops), giving date, volume, issue and page range. The list of periodicals indexed therein can be consulted at the following electronic address:

Articles in periodicals

Docherty JR. Subtypes of functional α1 and α2 adrenoceptors. Eur J Pharmacol . 1998; 361(1):1-15. Martins MBG, Martins AR, Cavalheiro AJ, Telascrêa M. Caracterização biométrica e química da folha de Mentha pulegium x spicata (Lamiaceae). Rev Ciênc Farm., Araraquara, 2004;25(1):17-23.

Articles without volume or issue number

Combes A. Etude d’excipents utilizes dans l’industrie pharmaceutique. STP Pharma 1989:766-90.

Articles without author

Coffee drinking and cancer of the pancreas [editorial]. Br Med J Clin Res. 1981 Sep 5;283(6292):628.

Articles from on-line periodical 

Rocha JSY, Simões BJG, Guedes GLM. Assistência hospitalar como indicador da desigualdade social.  Rev  Saúde  Pública  [Internet]  1997  [citado  1998  mar  23];31(5)479-87.  Disponível em:

Articles with Digital Object Identifier -DOI

Harrison JJ, Ceri H, Yerly J, Stremick CA, Hu Y, Martinuzzi R, Turner RJ. The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the Calgary Biofilm Device. Biol Proc Online [Internet]. 2006 [cited 2007 Jan 8];8(1):194-215.Available from: DOI: 10.1251/bpo127

Institution as an author or publisher

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension 2002; 40(5):679-86.

Institution as both author and Publisher

Brasil. Ministério da Saúde. Manual de controle das doenças sexualmente transmissíveis. 3ª ed. Brasília (DF); 1999.Ministerio de Salud de Nicaragua. Política nacional de salud 1997-2002: descentralización yautonomía. Managua: Ministerio de Salud; 2002. p.42-9.

Papers presented at a congress

Alencar LCE, Seidl EMF. Levantamento bibliográfico de estudos sobre doadoras de leite humano produzidos no Brasil. In: 2. Congresso Internacional de Bancos de Leite Humano; 2005; Brasília: Ministério da Saúde; 2005.Harley  NH.  Comparing  radon  daughter  dosimetric  and  risk  models.  In:  Gammage  RB,  Kay SV,   editors.   Indoor   air   and   human   Health.   Proceedings   of   the   Seventh   Life   Sciences Symposium; 1984 Oct 29-31; Knosxville, TN. Chelsea, MI: Lewis, 1985:69-78.


Goodman LS. The pharmacological basis of therapeutics. 2nd. ed. New York: Macmillan; 1955.Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th. ed. Chicago: McGraw-Hill; 2006.

Chapters in books

Laurenti R. A medida das doenças. In: Forattini OP. Ecologia, epidemiologia e sociedade. SãoPaulo: Artes Médicas; 1992. p.369-98

Editors, Organizers

Dienner HC, Wilkinson M, editors. Drug induced headache. New York: Spring-Verlag; 1988.

Book on CD-ROM

Martindale: the complete drug reference [CD-ROM]. Englewood, CO: Micromedex; 1999. Basedon: Parfitt K, editor. Martindale: the complete drug reference. London: Pharmaceutical Press; 1999. International Healthcare Series.

Dissertation and thesis

Gonçalves H. Aproveitar a vida: um estudo antropológico sobre valores, juventude e gravidezem uma cidade do interior [tese]. Porto Alegre: UFRGS; 2004.

Legal documents Published legislation

Brasil. Agência Nacional de Vigilância Sanitária. Resolução RDC nº 27, de 30 de março de 2007. Dispõesobre o Sistema Nacional de Gerenciamento de Produtos Controlados -SNGPC estabelece a implantação do módulo para drogarias e farmácias e dá outras providências. Diário Oficial da União, nº 63, 2 de abril de 2007. Seção 1. p. 62-4.São Paulo (Estado). Decreto no 42.822, de 20 de janeiro de 1998. Lex: coletânea de legislaçãoe jurisprudência, São Paulo, 1998; 62(3): 217-220.Planned legislationMedical Records Confidentiality Act of 1995, S. 1360, 104th Cong., 1st Sect. (1995). Federal code regulationsInformed Consent, 42 C.F.R. Sect. 441.257 (1995).


Harred JF, Knight AR, McIntyre JS, inventors. Dow Chemical Company, assignee. Expoxidation process. US patent 3,654,317. 1972 Apr 4.


HINTZE JL. NCSS: statistical system for Windows. Version 2001. Kaysville, UT: Number Cruncher Statistical Systems; 2002. Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and Prevention; 1994.EPI Info: a database and statistics program for public health professionals Version 3.2.2.Atlanta, GA: Centers for Disease Control and Prevention (CDC); 2005. [cited 2006 May 30].Available from: .


Health on the net foundation. Health on the net foundation code of conduct (HONcode) for medical and health websites. [cited 1998 June 30]. Available from: .Hoffman DL. St John’s Wort. 1995; [4 screens]. [cited 1998 July 16]. Available from: .

Publishing Agreement

The authors must read, understand and sign the publishing agreement.